• Black Diamond Therapeutics will host an investor webcast Nov. 10, 2026, at 7:30 a.m. ET.
• The webcast will cover updated Phase 2 silevertinib results in first-line EGFR-mutated non-small cell lung cancer.
• Discussion will include FDA feedback supporting a Phase 3 path to potential accelerated approval in that patient population.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Black Diamond Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611091601PRIMZONEFULLFEED9873587) on November 09, 2026, and is solely responsible for the information contained therein.